| Name | Title | Contact Details |
|---|
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
Breas was founded in 1991 in Gothenburg, Sweden and has become one of the global leaders in Home Mechanical Ventilation, Airway Clearance and Sleep therapy.
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. Enjoy working with our experts to accelerate your small molecule therapeutics into the market.
ABS Corporation is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Fisher Wallace Stimulator® is a wearable neurostimulation device cleared by the FDA to treat depression, anxiety and insomnia. During each 20-minute treatment session, the device gently stimulates the brain to produce serotonin and other neurochemi...